Key facts
- This page summarizes Robert R. Ruffolo's Form 4 filing for Sigilon Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2021, 16:16.
Robert R. Ruffolo - 01 Jul 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Jul 2021
- Net transaction value
- -$66,082
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2021, 16:16:05 UTC
- Prior SEC filing
- 28 Jun 2021
- Next SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Kowalsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert R. Ruffolo filed Form 4 for Sigilon Therapeutics, Inc. on 02 Jul 2021.
Change
- Previous filing in this sequence was filed on 28 Jun 2021.
- Current net transaction value: -$66,082.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGTX
transaction
Common Stock
Options Exercise
- Transaction value
- $3,848
- Shares
- +6,750
- Change %
- Price
- $0.5700
- Shares after
- 6,750
- Date
- 01 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
SGTX
transaction
Common Stock
Sale
- Transaction value
- $69,930
- Shares
- -6,750
- Change %
- -100%
- Price
- $10.36*
- Shares after
- 0
- Date
- 01 Jul 2021
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SGTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,750
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 48,805
- Date
- 01 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,750
- Exercise price
- $0.5700
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.